vs
Side-by-side financial comparison of Laird Superfood, Inc. (LSF) and Relay Therapeutics, Inc. (RLAY). Click either name above to swap in a different company.
Laird Superfood, Inc. is the larger business by last-quarter revenue ($13.3M vs $7.0M, roughly 1.9× Relay Therapeutics, Inc.).
Laird Superfood, Inc. develops, manufactures and sells a portfolio of plant-based functional superfood products, including premium coffee creamers, hydration blends, nutritional supplements, and plant-powered snacks. It serves health-conscious consumers through direct-to-consumer e-commerce platforms and offline retail partners, mainly operating in the North American market with a focus on sustainably sourced clean ingredients.
Relay Therapeutics is a clinical-stage biotechnology company focused on developing precision oncology therapies. It leverages advanced computational modeling of protein dynamics, paired with cutting-edge experimental biology, to design targeted medicines for previously intractable cancer types, serving global oncology care markets and patient populations.
LSF vs RLAY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.3M | $7.0M |
| Net Profit | $-1.8M | — |
| Gross Margin | 34.1% | — |
| Operating Margin | -13.5% | — |
| Net Margin | -13.2% | — |
| Revenue YoY | 15.0% | — |
| Net Profit YoY | -341.4% | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.3M | $7.0M | ||
| Q3 25 | $12.9M | $0 | ||
| Q2 25 | $12.0M | — | ||
| Q1 25 | $11.7M | $7.7M | ||
| Q4 24 | $11.6M | $0 | ||
| Q3 24 | $11.8M | $0 | ||
| Q2 24 | $10.0M | $0 | ||
| Q1 24 | $9.9M | $10.0M |
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $-975.1K | $-74.1M | ||
| Q2 25 | $-362.2K | — | ||
| Q1 25 | $-156.2K | $-77.1M | ||
| Q4 24 | $-398.4K | — | ||
| Q3 24 | $-166.1K | $-88.1M | ||
| Q2 24 | $-239.1K | $-92.2M | ||
| Q1 24 | $-1.0M | $-81.4M |
| Q4 25 | 34.1% | — | ||
| Q3 25 | 36.5% | — | ||
| Q2 25 | 39.9% | — | ||
| Q1 25 | 41.9% | — | ||
| Q4 24 | 38.6% | — | ||
| Q3 24 | 43.0% | — | ||
| Q2 24 | 41.8% | — | ||
| Q1 24 | 40.0% | — |
| Q4 25 | -13.5% | — | ||
| Q3 25 | -7.7% | — | ||
| Q2 25 | -3.3% | — | ||
| Q1 25 | -1.9% | -1105.2% | ||
| Q4 24 | -4.1% | — | ||
| Q3 24 | -2.3% | — | ||
| Q2 24 | -3.4% | — | ||
| Q1 24 | -11.0% | -903.0% |
| Q4 25 | -13.2% | — | ||
| Q3 25 | -7.6% | — | ||
| Q2 25 | -3.0% | — | ||
| Q1 25 | -1.3% | -1003.6% | ||
| Q4 24 | -3.4% | — | ||
| Q3 24 | -1.4% | — | ||
| Q2 24 | -2.4% | — | ||
| Q1 24 | -10.3% | -813.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.43 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-0.46 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.63 | ||
| Q2 24 | — | $-0.69 | ||
| Q1 24 | — | $-0.62 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.1M | $84.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $11.5M | $567.1M |
| Total Assets | $19.2M | $621.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.1M | $84.0M | ||
| Q3 25 | $5.1M | $91.6M | ||
| Q2 25 | $3.9M | — | ||
| Q1 25 | $7.0M | $93.5M | ||
| Q4 24 | $8.3M | $124.3M | ||
| Q3 24 | $7.9M | $152.4M | ||
| Q2 24 | $7.6M | $134.1M | ||
| Q1 24 | $7.1M | $152.9M |
| Q4 25 | $11.5M | $567.1M | ||
| Q3 25 | $12.8M | $607.7M | ||
| Q2 25 | $13.4M | — | ||
| Q1 25 | $13.3M | $721.1M | ||
| Q4 24 | $13.2M | $777.8M | ||
| Q3 24 | $13.1M | $838.9M | ||
| Q2 24 | $12.6M | $681.7M | ||
| Q1 24 | $12.7M | $745.8M |
| Q4 25 | $19.2M | $621.3M | ||
| Q3 25 | $18.9M | $670.0M | ||
| Q2 25 | $20.4M | — | ||
| Q1 25 | $21.5M | $799.4M | ||
| Q4 24 | $19.3M | $871.3M | ||
| Q3 24 | $18.8M | $930.1M | ||
| Q2 24 | $18.0M | $772.5M | ||
| Q1 24 | $17.6M | $841.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $68.4K | $-235.5M |
| Free Cash FlowOCF − Capex | — | $-235.9M |
| FCF MarginFCF / Revenue | — | -3370.0% |
| Capex IntensityCapex / Revenue | — | 5.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-622.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $68.4K | $-235.5M | ||
| Q3 25 | $1.2M | $-62.1M | ||
| Q2 25 | $-2.8M | — | ||
| Q1 25 | $-1.3M | $-73.2M | ||
| Q4 24 | $339.2K | $-249.1M | ||
| Q3 24 | $305.8K | $-75.1M | ||
| Q2 24 | $642.7K | $-65.8M | ||
| Q1 24 | $-422.3K | $-50.3M |
| Q4 25 | — | $-235.9M | ||
| Q3 25 | — | $-62.1M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-73.6M | ||
| Q4 24 | — | $-251.1M | ||
| Q3 24 | — | $-75.3M | ||
| Q2 24 | — | $-65.8M | ||
| Q1 24 | — | $-52.1M |
| Q4 25 | — | -3370.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -958.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -520.7% |
| Q4 25 | — | 5.9% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 17.8% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |
RLAY
Segment breakdown not available.
